Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accounts Payables: 2010-2025

Historic Accounts Payables for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $2.0 million.

  • OptimizeRx's Accounts Payables fell 2603.49% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 2603.49%. This contributed to the annual value of $2.2 million for FY2024, which is 318.81% down from last year.
  • As of Q3 2025, OptimizeRx's Accounts Payables stood at $2.0 million, which was down 2603.49% from $2.0 million recorded in Q2 2025.
  • OptimizeRx's Accounts Payables' 5-year high stood at $3.4 million during Q1 2025, with a 5-year trough of $499279.0 in Q1 2021.
  • In the last 5 years, OptimizeRx's Accounts Payables had a median value of $1.3 million in 2022 and averaged $1.5 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 3690.18% in 2023, then surged by 29846.11% in 2024.
  • Quarter analysis of 5 years shows OptimizeRx's Accounts Payables stood at $606808.0 in 2021, then skyrocketed by 155.43% to $1.5 million in 2022, then soared by 43.68% to $2.2 million in 2023, then dropped by 3.19% to $2.2 million in 2024, then dropped by 5.52% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.0 million for Q2 2025, and $3.4 million during Q1 2025.